CTRI/2017/10/010218
Active, not recruiting
Phase 4
A multi-centre prospective, non-interventional study of ability and willingness to pay for BIAsp 30 in a real world population with type 2 diabetes mellitus - NA
ovo Nordisk India Private Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ovo Nordisk India Private Ltd
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The decision to initiate treatment with commercially available BIAsp 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
- •2\. Patients selected by their physician for participation in the study, who are likely to be able and willing to pay for the BIAsp 30 treatment for at least 12 weeks from baseline visit as assessed by the treating physician.
- •3\. Signed informed consent obtained before any study\-related activities (study\-related activities are any procedure related to recording of data according to the protocol).
- •4\. Male or female more than or equal to 18 years at time of informed consent.
- •5\. Diagnosed with T2DM and treated with BHI in vials for at least three consecutive months at time of informed consent.
Exclusion Criteria
- •1\. Previous participation in this study. Participation is defined as having given informed consent in this study.
- •2\. Concurrent participation in any other clinical trial or study.
- •3\. Patients previously treated with insulin analogues.
- •4\. Known or suspected hypersensitivity to study product (or any of the excipients of the study product; a full list of excipients is provided in Summary of product characteristics (SmPC) of NovoMix® 3011\) or related products.
- •5\. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation.
- •6\. Patients who are unable to read or write (illiterate).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A non-interventional, prospective, multicenter study to describe patient preference and real-world outcomes of Diroximel Fumarate for the treatment of relapsing remitting multiple sclerosis in daily clinical practiceG35.1DRKS00029567Biogen GmbH118
Recruiting
Not Applicable
Prospective, multi-centre, non-interventional study on the use, tolerability and safety of the One Strength dose escalation scheme with NOVo Helisen® hoUSe dust mites in everyday practiceJ30.3J30.4H10.1J45.0Other allergic rhinitisAllergic rhinitis, unspecifiedAcute atopic conjunctivitisPredominantly allergic asthmaDRKS00032532Allergopharma GmbH & Co. KG1,000
Completed
Not Applicable
A multicenter, prospective, non-interventional observational study to determine LDL-C goal attainment rate in elderly patients with dyslipidemia receiving Mevalotin® Tab.KCT0003190Daiichi-Sankyo Korea3,000
Completed
Not Applicable
A prospective, controlled, multicentre non-interventional study of parenteral nutrition within the oncological outpatient careC00-C97Malignant neoplasmsDRKS00010078GHD GesundHeits GmbH Deutschland123
Recruiting
Not Applicable
A prospective, non-interventional, multicenter, observational study to investigate the effectiveness and safety of Sevikar HCT® Tablet in hypertensive patients with type 2 diabetes mellitus or prediabetes in KoreaDiseases of the circulatory systemKCT0006918Daiichi-Sankyo Korea3,000